Cancer Diagnostics Market Research Report - Forecast till 2027

Cancer Diagnostics Market Size, Trends and Industry Outlook by Type (Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma Cancer, Prostate Cancer, Liver Cancer and others), End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/MED/1430-HCR | August 2022 | Region: Global | 90 Pages         

Table of Contents

Chapter 1. Executive Summary

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

Chapter 5. Market Factor Analysis

5.1 Porterโ€™s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.2.1 R&D and Designing

5.2.2 Manufacturing

5.2.3 Distribution & Sales

5.2.4 Post-Sales Review

Chapter 6. Global Cancer Diagnostics Market, by Type

6.1 Overview

6.2 Imaging Testing

6.2.1 Magnetic Resonance Imaging (MRI)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2 Computed Tomography (CT)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3 Positron Emission Tomography (PET)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3.1 Standalone Positron Emission Tomography

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3.2 Hybrid Positron Emission Tomography

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.4 Mammography

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6. 2.5 Ultrasound

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Biomarkers Testing

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.1 Protein Biomarker

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2 Genetic Biomarker

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 In Vitro Diagnostic Testing

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.1 Polymerase Chain Reaction (PCR)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.2 In Situ Hybridization (ISH)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.3 Immunohistochemistry Testing (IHC)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.4 Next-Generation Sequencing Testing (NGS)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.5 Microarrays

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.6 Flow Cytometry

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.5 Molecular Diagnostics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4.6 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5 Biopsy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5.1 Needle Biopsy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5.2 Bone Marrow Biopsy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Cancer Diagnostics Market, by Application

7.1 Overview

7.2 Lung Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Breast Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Colorectal Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Melanoma Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Prostate Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.7 Liver Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.8 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Cancer Diagnostics Market, by End User

8.1 Overview

82 Diagnostic Center

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Research Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Cancer Diagnostics Market, by Region

9.1 Overview

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 Latin America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10 Company Landscape

10.1 Overview

10.2 Competitive Analysis

Chapter 11. Company Profile

11.1 Exact Sciences Corporation

11.1.1 Company Overview

11.1.2 Products/Services Offered

11.1.3 Financial Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.1.6 Key Strategies

11.2 Arquer Diagnostics Ltd

11.2.1 Company Overview

11.2.2 Products/Services Offered

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.2.6 Key Strategies

11.3 BioMark Diagnostics Inc.

11.3.1 Company Overview

11.3.2 Products/Services Offered

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.3.6 Key Strategies

11.4 Biotheranostics

11.4.1 Company Overview

11.4.2 Products/Services Offered

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.4.6 Key Strategies

11.5 Cancer Diagnostics, Inc.

11.5.1 Company Overview

11.5.2 Products/Services Offered

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.5.6 Key Strategies

11.6 Agilent Technologies, Inc.

11.6.1 Company Overview

11.6.2 Products/Services Offered

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.6.6 Key Strategies

11.7 Thermo Fisher Scientific, Inc.

11.7.1 Overview

11.7.2 Products/Services Offered

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7.6 Key Strategies

11.8 Illumina, Inc.

11.8.1 Overview

11.8.2 Products/Services Offered

11.8.3 Financial Overview

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8.6 Key Strategies

11.9 Becton, Dickinson and Company

11.9.1 Overview

11.9.2 Products/Services Offered

11.9.3 Financial Overview

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.9.6 Key Strategies

11.10 GE Healthcare

11.10.1 Overview

11.10.2 Products/Services Offered

11.10.3 Financial Overview

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.10.6 Key Strategies

11.11 QIAGEN N.V.

11.11.1 Overview

11.11.2 Products/Services Offered

11.11.3 Financial Overview

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.11.6 Key Strategies

11.12 Abbott Laboratories, Inc.

11.12.1 Overview

11.12.2 Products/Services Offered

11.12.3 Financial Overview

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.12.6 Key Strategies

11.13 Roche Diagnostics

11.13.1 Overview

11.13.2 Products/Services Offered

11.13.3 Financial Overview

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.13.6 Key Strategies

11.14 Siemens Healthcare

11.14.1 Overview

11.14.2 Products/Services Offered

11.14.3 Financial Overview

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.14.6 Key Strategies

11.15 Koninklijke Philips N.V.

11.15.1 Overview

11.15.2 Products/Services Offered

11.15.3 Financial Overview

11.15.4 Key Developments

11.15.5 SWOT Analysis

11.15.6 Key Strategies

11.16 Others

Chapter 12 Appendix

12.1 References

12.2 Related Reports

โ€ƒ

LIST OF TABLES

Table 1 Global Cancer Diagnostics Market Synopsis, 2020-2027

Table 2 Global Cancer Diagnostics Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 4 Global Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 5 Global Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

Table 6 Global Cancer Diagnostics Market, by Region, 2020-2027 (USD Million)

Table 7 Americas: Cancer Diagnostics Market, by Region, 2020 and 2025

Table 8 Americas: Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 9 Americas: Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 10 Americas: Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

Table 11 North America: Cancer Diagnostics Market, by Country, 2020-2027 (USD Million)

Table 12 North America: Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 13 North America: Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 14 North America: Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

Table 15 US: Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 16 US: Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 17 US: Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

Table 18 Canada: Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 19 Canada: Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 20 Canada: Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

Table 21 Latin America: Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 22 Latin America: Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 23 Latin America: Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

Table 24 Europe: Cancer Diagnostics Market, by Region, 2020-2027 (USD Million)

Table 25 Europe: Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 26 Europe: Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 27 Europe: Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

Table 28 Western Europe: Cancer Diagnostics Market, by Country, 2020-2027 (USD Million)

Table 29 Western Europe: Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 30 Western Europe: Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 31 Western Europe: Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

Table 32 Eastern Europe: Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 33 Eastern Europe: Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 34 Eastern Europe: Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

Table 35 Asia-Pacific: Cancer Diagnostics Market, by Country, 2020-2027 (USD Million)

Table 36 Asia-Pacific: Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 37 Asia-Pacific: Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 38 Asia-Pacific: Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

Table 39 Middle East & Africa: Cancer Diagnostics Market, by Region, 2020-2027 (USD Million)

Table 40 Middle East & Africa: Cancer Diagnostics Market, by Type, 2020-2027 (USD Million)

Table 41 Middle East & Africa: Cancer Diagnostics Market, by Application, 2020-2027 (USD Million)

Table 42 Middle East & Africa: Cancer Diagnostics Market, by End User, 2020-2027 (USD Million)

โ€ƒ

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Market Structure of the Global Cancer Diagnostics Market

Figure 3 Market Dynamics of the Global Cancer Diagnostics Market

Figure 4 Global Cancer Diagnostics Market Share, by Type, 2020 (%)

Figure 5 Global Cancer Diagnostics Market Share, by Type, 2020 (USD Million)

Figure 6 Global Cancer Diagnostics Market Share, by Application, 2020 (%)

Figure 7 Global Cancer Diagnostics Market Share, by Application, 2020 (USD Million)

Figure 8 Global Cancer Diagnostics Market Share, by End User, 2020 (%)

Figure 9 Global Cancer Diagnostics Market Share, by End User, 2020 (USD Million)

Figure 10 Global Cancer Diagnostics Market Share, by Region, 2020 (%)

Figure 11 Americas: Cancer Diagnostics Market Share, by Region, 2020 (%)

Figure 12 North America: Cancer Diagnostics Market Share, by Country, 2020 (%)

Figure 13 Europe: Cancer Diagnostics Market Share, by Region, 2020 (%)

Figure 14 Western Europe: Cancer Diagnostics Market Share, by Country, 2020 (%)

Figure 15 Asia-Pacific: Cancer Diagnostics Market Share, by Country, 2020 (%)

Figure 16 Middle East & Africa: Cancer Diagnostics Market Share, by Region, 2020 (%)

Figure 17 Global Cancer Diagnostics Market: Company Share Analysis, 2020 (%)

Figure 18 Exact Sciences Corporation: Key Financials

Figure 19 Exact Sciences Corporation: Segmental Revenue

Figure 20 Exact Sciences Corporation: Regional Revenue

Figure 21 Arquer Diagnostics Ltd: Key Financials

Figure 22 Arquer Diagnostics Ltd: Segmental Revenue

Figure 23 Arquer Diagnostics Ltd: Regional Revenue

Figure 24 BioMark Diagnostics Inc.: Key Financials

Figure 25 BioMark Diagnostics Inc.: Segmental Revenue

Figure 26 BioMark Diagnostics Inc.: Regional Revenue

Figure 27 Biotheranostics: Key Financials

Figure 28 Biotheranostics: Segmental Revenue

Figure 29 Biotheranostics: Regional Revenue

Figure 30 Cancer Diagnostics, Inc.: Key Financials

Figure 31 Cancer Diagnostics, Inc.: Segmental Revenue

Figure 32 Cancer Diagnostics, Inc.: Regional Revenue

Figure 33 Agilent Technologies, Inc.: Key Financials

Figure 34 Agilent Technologies, Inc.: Segmental Revenue

Figure 35 Agilent Technologies, Inc.: Regional Revenue

Figure 36 Thermo Fisher Scientific, Inc.: Key Financials

Figure 37 Thermo Fisher Scientific, Inc.: Segmental Revenue

Figure 38 Thermo Fisher Scientific, Inc.: Regional Revenue

Figure 39 Illumina, Inc.: Key Financials

Figure 40 Illumina, Inc.: Segmental Revenue

Figure 41 Illumina, Inc.: Regional Revenue

Figure 42 Becton, Dickinson and Company: Key Financials

Figure 43 Becton, Dickinson and Company: Segmental Revenue

Figure 44 Becton, Dickinson and Company: Regional Revenue

Figure 45 GE Healthcare: Key Financials

Figure 46 GE Healthcare: Segmental Revenue

Figure 47 GE Healthcare: Regional Revenue

Figure 48 QIAGEN N.V.: Key Financials

Figure 49 QIAGEN N.V.: Segmental Revenue

Figure 50 QIAGEN N.V.: Regional Revenue

Figure 51 Abbott Laboratories, Inc.: Key Financials

Figure 52 Abbott Laboratories, Inc.: Segmental Revenue

Figure 53 Abbott Laboratories, Inc.: Regional Revenue

Figure 54 Roche Diagnostics: Key Financials

Figure 55 Roche Diagnostics: Segmental Revenue

Figure 56 Roche Diagnostics: Regional Revenue

Figure 57 Siemens Healthcare: Key Financials

Figure 58 Siemens Healthcare: Segmental Revenue

Figure 59 Siemens Healthcare: Regional Revenue

Figure 60 Koninklijke Philips N.V.: Key Financials

Figure 61 Koninklijke Philips N.V.: Segmental Revenue

Figure 62 Koninklijke Philips N.V.: Regional Revenue

Cancer Diagnostics Market

Cancer Diagnostics Market is expected to register a CAGR of 8.12% to reach USD 163,000 million by 2027.

Segmentation

By Type Imaging Testing Biomarkers Testing In Vitro Diagnostic Testing Biopsy And Others
By Application Lung Cancer Breast Cancer Colorectal Cancer Melanoma Cancer Prostate Cancer Liver Cancer Others
By End-User Diagnostic Centers Hospitals And Clinics Research Institutes Others

Key Players

  • Exact Sciences Corporation
  • Arquer Diagnostics Ltd
  • BioMark Diagnostics Inc.
  • Biotheranostics
  • Cancer Diagnostics
  • Agilent Technologies
  • Thermo Fisher Scientific
  • Illumina
  • Becton Dickinson and Company (BD)
  • GE Healthcare
  • QIAGEN N.V.
  • Abbott Laboratories

Drivers

  • Growing oncologic case prevalence
  • rising need for efficient screening tests
  • Raising awareness
Speak to Analyst Request a Free Sample

Cancer Diagnostics Market Overview


The cancer diagnostics market was valued USD 122,000 million in 2018 and  expected to reach USD 163,000 million,  at a CAGR of 8.9% over the projected period. Cancer is one of the leading causes of death globally, and its prevalence is on the rise. As a result, healthcare providers concentrate on establishing efficient diagnostic and therapeutic solutions to ascertain the prevalence level. As the demand for diagnostic imaging treatments develops and public hospitals struggle to keep up with the limited number of imaging modalities at their disposal, the number of independent diagnostic centers is spreading worldwide.


Over the projected period, the cancer diagnostics market is anticipated to grow due to amplified mortality and various cancers, such as breast cancer and lung cancer. Also, the cancer diagnostics market will profit from a surge in advancing technology that aid in improved scanning of cancerous cells, improvements in equipment to diagnose the kind of cancer, and an increase in output of the results during the projected period. Many hospitals in poorer countries cannot invest in diagnostic imaging technology due to decreased payback rates, greater prices, and budgetary constraints. However, hospitals that cannot afford new imaging equipment opt for used systems due to the expanding need for diagnostic imaging services in these nations.


Covid 19 Analysis


With the World Health Organization officially declaring the COVID-19 outbreak a pandemic, a coalition of established pharmaceutical and biopharmaceutical companies, as well as small startups, has stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus. The COVID-19 pandemic has had a substantial influence on the availability of hospital services around the world. This has mostly been addressed by drastically lowering inpatient and outpatient treatment for various diseases, as well as instituting infection prevention and control methods. With the epidemic affecting countries all over the world, the number of cancer screening and diagnostic treatments has plummeted significantly.


Cancer Diagnostics Market Dynamic



  •         Drivers


The number of private diagnostic of cancer is expanding across the world since there is a growing demand for diagnostic imaging treatments and a growing load on public hospitals due to a restricted number of imaging modalities. Growing oncologic case prevalence, continual technical improvements in diagnostics, and the rising need for efficient screening tests are some of the primary drivers driving the global need for screening tools and procedures. Raising awareness and supporting government efforts are two other factors that are expected to drive Cancer Diagnostics Market expansion over the projected period.



  •         Opportunities


Cancer screening tests are being recommended for people by governments in industrialized nations and primary care doctors in an effort to detect cancer in its early stages and reduce death rates which are ultimately creating major opportunities for the key players of the cancer diagnostics market.



  •         Restraints


High-cost treatment and inadequate reimbursement policies in underdeveloped nations are some of the factors that may impede cancer diagnostics market growth over the forecast period.



  •         Challenges


Due to increased costs, lower reimbursement rates, and budgetary restrictions, many hospitals in poorer nations are unable to invest in diagnostic imaging technology. However, because of the increasing demand for diagnostic imaging operations in these countries, hospitals that cannot afford to purchase new imaging equipment choose to use secondhand equipment. Refurbished systems are less expensive than new systems, costing between 40% and 60% of the original purchase price.


Many industry leaders are now advertising reconditioned gadgets through various programmers as a result of this. Some notable worldwide refurbishment initiatives that promote the use of reconditioned diagnostic imaging equipment include Siemens' Medical Proven Excellence Program, GE Healthcare's Gold Seal Program, and Philips' Diamond Select Program.


Cumulative Growth Analysis


In Bangalore, India, FUJIFILM Corporation established NURA, a cancer screening facility, in January 2021. FUJIFILM DKH LLP (FUJIFILM DKH) and Dr. Kutty's Healthcare jointly manage this medical screening center (DKH). FUJIFILM DKH LLP (FUJIFILM DKH) is a joint venture between FUJIFILM and Dr. Kutty's Healthcare (DKH), a hospital and screening center operator in India and the Middle East.


Value Chain Analysis


According to the reports, type, application, end-user, and region are the segments that make up the worldwide cancer diagnostics market. Imaging testing, biomarkers testing, in vitro diagnostic testing, biopsy, and others make up the global market for cancer diagnostics. Magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) are the three types of imaging tests (PET).


The worldwide cancer diagnostics market is divided into lung cancer, breast cancer, colorectal cancer, melanoma cancer, prostate cancer, liver cancer, and others based on application. The worldwide market is divided into diagnostic centers, hospitals and clinics, research institutes, and others based on the end-user. The aforementioned segments are covered by four areas in the present scope of the study: the Americas, Europe, Asia-Pacific, and the Middle East, and Africa. The market for cancer diagnostics in the Americas has been separated into North America and South America, with the North American market separated into the United States and Canada.


Regional Market Summary


Global Cancer Diagnostics Market Share (%), by Region, 2018  Cancer Diagnostics Market


Sources: MRFR Analysis


Segmentation Overview


The cancer diagnostics market is segmented on the basis of type, application, end-user, and region. The global market is expected to witness decent growth during the forecast period.


By Application


Based on the application, the cancer diagnostics market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma cancer, prostate cancer, liver cancer, and others.


 By end-users


Based on the propulsion types, the cancer diagnostics market is segmented into diagnostic centers, hospitals and clinics, research institutes, and others.


Regional Analysis


Because of the region's expanding elderly population, rising healthcare spending, and well-established healthcare industry, the Americas led the cancer diagnostics market. According to research provided by the American Cancer Society, cancer is most commonly discovered in geriatric people (55 years or older), and cancer affects roughly 80% of the population in the United States. Europe accounted for the second-largest proportion of the cancer diagnostics market in 2018. The regional market is predicted to develop due to raising cancer awareness, technological improvements in the region, and the rising need for effective cancer treatment and diagnostics. In the European cancer diagnostics market, Germany had the greatest share. For example, according to the World Cancer Research Fund International in 2018, Oceania, Europe, and North America had the highest cancer rates.


Due to the existence of a large patient pool and rising government efforts for the expansion of the healthcare sector in the area, the cancer industry profit in Asia-Pacific (APAC) is predicted to develop at the quickest rate during the projected period. Asia-Pacific countries are embracing sophisticated treatment alternatives, which is driving market expansion in the area. Furthermore, the existence of growing nations like China, India, and Japan is likely to fuel market expansion.


Competitive landscape


GE Healthcare, Abbott, F. Hoffmann-La Roche Ltd, and Siemens Healthcare GmbH are just a few of the major participants in the cancer diagnostics companies. These firms have a prominent presence in the worldwide market, owing to their adoption of novel goods and their extensive R&D efforts to offer advancements in the field.


Major Key Players



  •         Exact Sciences Corporation

  •         Arquer Diagnostics Ltd

  •         BioMark Diagnostics Inc.

  •         Biotheranostics, Cancer Diagnostics, Inc.

  •         Agilent Technologies, Inc.

  •         Thermo Fisher Scientific, Inc.

  •         Illumina, Inc.

  •         Becton, Dickinson and Company (BD)

  •         GE Healthcare

  •         QIAGEN N.V.

  •         Abbott Laboratories, Inc.

  •         Roche Diagnostics

  •         Siemens Healthcare

  •         Koninklijke Philips N.V., Inc.


Recent Developments



  • Feb 2022 Crosscope Inc., a leading provider of AI-enabled digital pathology software, and Mindpeak Gmbh, a company specializing in developing sophisticated AI tools for clinical diagnosis, have announced a partnership to integrate Mindpeak's image analysis tools into Crosscope's Digital Pathology platform. Crosscope will expand its AI application portfolio and provide end-to-end digital pathology solutions due to this agreement. Mindpeak has created software that analyzes immunohistochemically stained tissue samples and detects, classifies, and quantifies breast cancer cells in real-time.

  • Feb 2022 Cleveland Diagnostics, Inc., a clinical-stage biotechnology firm developing next-generation diagnostic tests for cancer early detection, revealed the release of a significant real-world clinical utility study in Urology Practice, an American Urological Association peer-reviewed journal.


Market Segmentation


Global Cancer Diagnostics Market, by Type


Imaging Testing



  • Magnetic Resonance Imaging (MRI)

  • Computed Tomography (CT)

  • Positron Emission Tomography (PET)

  • Standalone Positron Emission Tomography

  • Hybrid Positron Emission Tomography

  • Mammography

  • Ultrasound

  • Others


Biomarkers Testing



  • Protein Biomarker

  • Genetic Biomarker

  • Others


In Vitro Diagnostic Testing



  • Polymerase Chain Reaction (PCR)

  • In Situ Hybridization (ISH)

  • Immunohistochemistry Testing (IHC)

  • Next-Generation Sequencing Testing (NGS)

  • Microarrays

  • Flow Cytometry

  • Molecular Diagnostics

  • Others


Biopsy



  • Needle Biopsy

  • Bone Marrow Biopsy


Cancer Diagnostics Market, by Application



  • Lung Cancer

  • Breast Cancer

  • Colorectal Cancer

  • Melanoma Cancer

  • Prostate Cancer

  • Liver Cancer

  • Others


Cancer Diagnostics Market, by End User



  • Diagnostic Centers

  • Hospitals and Clinics

  • Research Institutes

  • Others


Region



  • North America


    • US

    • Canada


  • Europe


    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe


  • Asia-Pacific


    • China


      • Japan

      • India

      • Australia

      • South Korea

      • Rest of Asia-Pacific



  • Rest of the World


    • Middle East

    • Africa

    • Latin America




Report Scope:
Report Attribute/Metric Details
  Market Size   2025 : USD 163,000 Million
  CAGR   8.9% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Application, End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Exact Sciences Corporation, Arquer Diagnostics Ltd, BioMark Diagnostics Inc., Biotheranostics, Cancer Diagnostics, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Becton, Dickinson and Company (BD), GE Healthcare, QIAGEN N.V., Abbott Laboratories, Inc., Roche Diagnostics, Siemens Healthcare, and Koninklijke Philips N.V. Inc.
  Key Market Opportunities   high-cost treatment and poor reimbursement policies in the developing countries of the world
  Key Market Drivers   increasing awareness about cancer, technological advancements in the region, and growing demand for efficient treatment and diagnostics for cancer


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The global cancer diagnostics market can touch a valuation of USD 163,000 million by 2025.

The global cancer diagnostics market was valued at USD 122,000 million in 2018.

The global cancer diagnostics market is expected to exhibit a CAGR of 8.9% from 2019 to 2025.

Large number of cancer patients can drive the global cancer diagnostics market from 2019 to 2025.

High costs of cancer treatment and lack of reimbursement policies pose a major challenge to the global cancer diagnostics market.

The Americas can dominate the global cancer diagnostics market till 2025.

Siemens Healthcare, Abbott Laboratories, Inc., BioMark Diagnostics Inc., QIAGEN N.V., Becton, Dickinson and Company (BD), Exact Sciences Corporation, Cancer Diagnostics, Inc., Roche Diagnostics, Arquer Diagnostics Ltd, Biotheranostics, Illumina, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Koninklijke Philips N.V., Inc., and GE Healthcare are major players of the global cancer diagnostics market.